Analysis of the effectiveness of different schemes of supportive therapy in the prophylaxis of cisplatin-induced nephrotoxicity
DOI:
https://doi.org/10.30968/rbfhss.2024.152.1119Abstract
Objective: To evaluate, in the scenario of rapid infusion, the effectiveness of the different regimens of supportive therapy employed in the prevention of nephrotoxicity and electrolyte depletion induced by cisplatin (CDDP). Methods: Data from patients who used CDDP weekly (30 to 40mg/m2) with an infusion time of 60-120 minutes were analyzed. The regimens evaluated were: saline solution (A), saline solution and mannitol (B), saline solution and magnesium (C) and saline solution with mannitol and magnesium (D). The following laboratory parameters were evaluated: creatinine (Cr), magnesium (Mg) sodium (Na) and potassium (K), and glomerular filtration rate (GFR). They were subsequently compiled in Microsoft Office Excel® and analyzed in Software R, using with analysis by means of descriptive statistics, developed in accordance with the recommendations of Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement. Results: The study population evaluated were 46 patients, who received 218 infusions of CDDP. It was observed that schemes A and B had a progressive decrease in Mg. Scheme B had decreased levels of K, Cr and increased Na. In the individual analysis of each cycle, the different schemes of supportive therapy in rapid infusion were equally effective in preventing nephrotoxicity and electrolyte depletion. The schemes used were evaluated for throughout CDDP administrations, the regimen C and D demonstrated efficacy in maintaining renal function throughout multiple administration of CDDP. Conclusion: In the analysis of cumulative doses, regimen C proved to be effective in preserving renal function throughout CDDP administrations. In the individual analysis of each cycle, regardless of the number of times CDDP was administered, protocols C and D, which contained Mg supplementation associated or not with mannitol, were equally effective in preventing nephrotoxicity.
Downloads
References
Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018; 31(1):15-25. doi: 10.1007/s40620-017-0392-z.
OMS . Estatísticas da Saúde Mundial 2020: Monitorando a Saúde para os ODS. Vol. 21. Organização Mundial da Saúde; Genebra, Suíça: 2020. pp. 1–9.
Loren P, Saavedra N, Saavedra K, et al. Epigenetic Mechanisms Involved in Cisplatin-Induced Nephrotoxicity: An Update. Pharmaceuticals (Basel). 2021 ; 21;14(6):491. doi: 10.3390/ph14060491.
Burns CV, Edwin SB, Szpunar S, et al. Cisplatin-induced nephrotoxicity in an outpatient setting. Pharmacotherapy. 2021; 41(2):184-190. doi: 10.1002/phar.2500.
Mense ES, Smit AAJ, Crul M, et al. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma. J Clin Pharm Ther. 2019; 44(2):249-257. doi: 10.1111/jcpt.12781.
Niggebrugge-Mentink KL, Beex-Oosterhuis MM, Ter Horst PGJ, et al. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-smallcell lung cancer: A retrospective cohort study (HYCIS-XL). J Clin Pharm Ther. 2020; 45(5):1153-1158. doi: 10.1111/jcpt.13200.
Crona DJ, Faso A, Nishijima TF, et al. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist. 2017; 22(5):609-619. doi: 10.1634/theoncologist. 2016-0319.
Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
J Clin Epidemiol. 2008; 61(4):344-9. doi: 10.1016/j.jclinepi.2007.11.008.
Mach CM, Kha C, Nguyen D, et al. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. J Clin Pharm Ther. 2017; 42(3):286-291. doi: 10.1111/jcpt.12509.
Kamacı ŞÇ, Koçak G, Yeşilova A, Cihan Ş. Evaluation of acute and chronic nephrotoxicity in patients received cisplatin-based chemotherapy: has anything changed over time? Int Urol Nephrol. 2022; 54(5):1085-1090. doi: 10.1007/s11255-021-02975-8.
Li S, He X, Ruan L, et al. Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 16;11:804685. doi: 10.3389/fonc.2021.804685.
Williams RP Jr, Ferlas BW, Morales PC, et al. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center. J Oncol Pharm Pract. 2017; 23(6):422-428. doi: 10.1177/1078155216656927.
Santoso JT, Lucci JA 3rd, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003; 52(1):13-8. doi: 10.1007/s00280-003-0620-1.
Minzi OMS, Lyimo TE, Furia FF, et al. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin. BMC Pharmacol Toxicol. 2020; 23;21(1):69. doi: 10.1186/s40360-020-00448-9.
National Comprehensive Cancer Network (NCCN)/NCCN Chemotherapy order templates. Available in: http:www.nccn.org/ ordertemplates. Accessed: 13rd Oct 2023.
Cancer Institute NSW Government, EVIQ, Australia. Available in: https://www.eviq.org.au/. Accessed: 9th May 2024.
Wales Cancer Network, Guideline for Management of Hydration During Systemic Anti-Cancer Therapy Containing Cisplatin, United-Kingdom, Version 1.0, January, 2023. Available in: https://executive.nhs.wales/functions/networks-and-planning /cancer/clinical-hub/systemic-anti-cancer-therapies-sact/sact-accordion/wcn-guideline-for-management-of-hydration-during-systemic-anti-cancer-therapy-containing-cisplatin/. Accessed: 9th May 2024.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
